(Adds: Revance Therapeutics, Enterprise Bancorp, Novolex, Arthur J Gallagher, Dow Updates: Omnicom Group)
Dec 9 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1430 GMT on Monday:
** Anti-wrinkle injection maker Revance Therapeutics
has agreed to be bought for $3.10 per share by privately held Crown Laboratories, instead of the $6.66 per share agreed previously, the two companies said.
** Enterprise Bancorp and Independent Bank
, the parent of Rockland Trust, have agreed to merge in a cash-and-stock deal valued at $562 million, they said, as regional lenders continue to consolidate their operations.
** Apollo Global Management-owned Novolex will buy packaging products maker Pactiv Evergreen in a $6.7 billion deal, the companies said.
** Arthur J Gallagher said it would acquire insurance broker AssuredPartners in an all-cash deal worth $13.45 billion, as it looks to bolster its focus on property and casualty and employee benefits across the U.S.
** Omnicom Group has struck a $13.25 billion all-stock deal to buy rival Interpublic Group , creating the world's largest advertising agency as traditional players look to better compete with Big Tech firms amid accelerating use of AI.
** Dow said it would sell a 40% stake in some U.S. Gulf Coast infrastructure assets to a fund managed by Macquarie Asset Management for $2.4 billion as it looks to focus more on its core chemicals business.
** Nature Infrastructure Capital and Davidson Kempner Capital Management said that they had jointly acquired the Dutch-based solar power and storage project development platform of Greencells Group.
(Compiled by Rajarshi Roy and Kamal Choudhury in Bengaluru)
((Rajarshi.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.